Financing Supports Pivotal Trial of PQ Bypass' Detour System


January 8, 2019—PQ Bypass, Inc. announced that it has entered into an agreement that provides for up to an aggregate of $60 million in equity financing that will be used to advance the clinical development of the company’s technology for the treatment of long blockages in leg arteries caused by peripheral artery disease. The financing will also allow the company to convert approximately $15 million in outstanding convertible debt and interest to equity.

The funding will support the DETOUR II pivotal trial, which is evaluating the safety and effectiveness of the company's Detour system to create a percutaneous femoropopliteal bypass. Currently underway, the trial will enroll up to 292 patients at up to 40 sites across the United States and Europe. DETOUR's National Coprincipal Investigators are Sean Lyden, MD, and Jihad Mustapha, MD.

In March 2017, PQ Bypass received European CE Mark approval for the Detour system. The Detour system is an investigational device and is limited by United States law to investigational use only.

The financing round is led by Deerfield Management and includes existing investors Seroba Life Sciences and MedTech Venture Partners.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.